2004
DOI: 10.1345/aph.1d312
|View full text |Cite
|
Sign up to set email alerts
|

Isotretinoin in the Treatment of Granuloma Annulare

Abstract: Isotretinoin should be reserved for patients with disseminated or refractory GA. Potential serious adverse effects associated with its use require careful monitoring.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
10
0
2

Year Published

2006
2006
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(12 citation statements)
references
References 16 publications
0
10
0
2
Order By: Relevance
“…The inflammatory cell infiltrate seen in GA is comprised of T lymphocytes and macrophages . This idiopathic reaction is believed to be a type‐IV hypersensitivity response to an unidentified antigen …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The inflammatory cell infiltrate seen in GA is comprised of T lymphocytes and macrophages . This idiopathic reaction is believed to be a type‐IV hypersensitivity response to an unidentified antigen …”
Section: Introductionmentioning
confidence: 99%
“…7 This idiopathic reaction is believed to be a type-IV hypersensitivity response to an unidentified antigen. 1,3,8,9 Possible relationships have been reported between GA and diabetes mellitus, thyroid diseases, lipid metabolic disorders, lymphoma and other malignant diseases, insect bites, acquired immunodeficiency syndrome and other viral infections. 10 The familial occurrence of GA appears to be rare, and only a few cases have been reported.…”
Section: Introductionmentioning
confidence: 99%
“…Several reports detail the successful use of isotretinoin 0.5-1 mg/kg/day, primarily in the disseminated form of the disease. Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy [134].…”
Section: Disseminated Granuloma Annularementioning
confidence: 99%
“…These cases clearly represent a major therapeutic challenge and many patients remain troubled by the appearance. The visible and unsightly nature of this skin condition has led to the proposal of a variety of topical and/or systemic treatment methods [5][6][7][8][9][10][11][12][13][14][15] (Table 1)-all with varying degrees of success and each with its own treatment-associated morbidity.…”
Section: Introductionmentioning
confidence: 99%